Cargando…

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korell, Felix, Laier, Sascha, Sauer, Sandra, Veelken, Kaya, Hennemann, Hannah, Schubert, Maria-Luisa, Sauer, Tim, Pavel, Petra, Mueller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael, Schmitt, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290830/ https://www.ncbi.nlm.nih.gov/pubmed/32429189 http://dx.doi.org/10.3390/cells9051225

Ejemplares similares

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
por: Korell, Felix, et al.
Publicado: (2021)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
por: Korell, Felix, et al.
Publicado: (2022)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
por: Schubert, Maria-Luisa, et al.
Publicado: (2020)

Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing
por: Noaks, Elsa, et al.
Publicado: (2021)

Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR
por: Schanda, Nicola, et al.
Publicado: (2021)

Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
por: Yang, Mingya, et al.
Publicado: (2020)

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
por: Schubert, Maria-Luisa, et al.
Publicado: (2023)

T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy
por: Wada, Fumiya, et al.
Publicado: (2022)

Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies
por: Wang, Sanmei, et al.
Publicado: (2021)

Impact of serum-free media on the expansion and functionality of CD19.CAR T-cells
por: Eberhardt, Franziska, et al.
Publicado: (2023)

Leukapheresis and Hyperleukocytosis, Past and Future
por: Zhang, Dongdong, et al.
Publicado: (2021)

Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients
por: Kunz, Alexander, et al.
Publicado: (2020)

Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
por: Farina, Mirko, et al.
Publicado: (2022)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation
por: Korell, Felix, et al.
Publicado: (2022)

Effect of leukapheresis on pain reduction in leukemic priapism
por: Noushad, Shahida, et al.
Publicado: (2022)

A proposed predictive mathematical model for efficient T-cell collection by leukapheresis for manufacturing chimeric antigen receptor T cells
por: Huang, Xinxin, et al.
Publicado: (2023)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
por: Brysting, Josephine, et al.
Publicado: (2023)

Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
por: Dreger, P., et al.
Publicado: (1993)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
por: de Vos, S, et al.
Publicado: (2018)

Therapeutic Leukapheresis: Experience of a Single Oncologic Centre
por: Rosales, Maria, et al.
Publicado: (2022)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
por: Zhang, Jiqin, et al.
Publicado: (2022)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
por: Schultz, Liora, et al.
Publicado: (2020)

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
por: Schubert, Maria-Luisa, et al.
Publicado: (2019)

Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients
por: Schubert, Maria-Luisa, et al.
Publicado: (2022)

The factors influencing clinical outcomes after leukapheresis in acute leukaemia
por: Lee, Howon, et al.
Publicado: (2021)

Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
por: Jo, Tomoyasu, et al.
Publicado: (2023)

P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY.
por: Farina, M., et al.
Publicado: (2022)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
por: Zinzani, P. L., et al.
Publicado: (2013)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_enrooh4mf7j070snr2ncpvo9st